These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 12851876)

  • 21. The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b.
    Gu J; Sun R; Shen S; Yu Z
    Pak J Pharm Sci; 2015 Jul; 28(4 Suppl):1493-7. PubMed ID: 26431662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants.
    Wu IC; Shiffman ML; Tong MJ; Marcellin P; Mondou E; Frederick D; Snow-Lampart A; Sorbel J; Rousseau F; Chang TT
    Clin Infect Dis; 2008 Nov; 47(10):1305-11. PubMed ID: 18840078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical analysis of hepatitis B virus mutations related to adefovir dipivoxil among patients with chronic hepatitis B virus infection in eastern Zhejiang province].
    Hu AR; Jiang SW; Li L; Ding SX; Hu YR; Liang XY
    Zhonghua Yi Xue Za Zhi; 2012 Jul; 92(27):1878-81. PubMed ID: 23134956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
    J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adefovir dipivoxil: a review of its use in chronic hepatitis B.
    Dando T; Plosker G
    Drugs; 2003; 63(20):2215-34. PubMed ID: 14498759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.
    Westland CE; Yang H; Delaney WE; Gibbs CS; Miller MD; Wulfsohn M; Fry J; Brosgart CL; Xiong S;
    Hepatology; 2003 Jul; 38(1):96-103. PubMed ID: 12829991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Compare the effect of combined therapy between telbivudine plus adefovir dipivoxil and lamivudine plus adefovir dipivoxil corresponding to renal function in patients with hepatitis B virus infection].
    Xu J; Bao L; Wang Y; Yang L; Li WT; Zhao ZH; Li Y
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):288-293. PubMed ID: 29996341
    [No Abstract]   [Full Text] [Related]  

  • 29. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine.
    Hosaka T; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Someya T; Sezaki H; Akuta N; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2007 May; 42(5):368-74. PubMed ID: 17530361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.
    Perrillo R; Hann HW; Mutimer D; Willems B; Leung N; Lee WM; Moorat A; Gardner S; Woessner M; Bourne E; Brosgart CL; Schiff E
    Gastroenterology; 2004 Jan; 126(1):81-90. PubMed ID: 14699490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A study on the treatment of chronic hepatitis B with YMDD mutation].
    Qiu YW; Jiang XH; Huang LH; Hu TH; Ding H; Jiang YM; Dai YX; Zhou M
    Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):171-4. PubMed ID: 19335977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
    Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of patients with chronic hepatitis B with adefovir dipivoxil.
    Tong MJ; Tu SS
    Semin Liver Dis; 2004; 24 Suppl 1():37-44. PubMed ID: 15192800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection.
    Gornals JB; Casanovas T; Sabidó M; Baliellas C; Casanovas A; Cañas C; Serrano T; Verdura B; Chahri N; Gil-Vernet S; Figueras J
    Transplant Proc; 2005 Nov; 37(9):3957-9. PubMed ID: 16386595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B].
    Zhao H; Zhang YX; Chen XY; Wang L; Tang XP; Si CW
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):294-7. PubMed ID: 17637268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
    Chan HL; Heathcote EJ; Marcellin P; Lai CL; Cho M; Moon YM; Chao YC; Myers RP; Minuk GY; Jeffers L; Sievert W; Bzowej N; Harb G; Kaiser R; Qiao XJ; Brown NA;
    Ann Intern Med; 2007 Dec; 147(11):745-54. PubMed ID: 17909201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B].
    Xu Z; Chen LB; Cao H; Shu X; Xu QH; Li G; Xie QF
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Jun; 24(3):224-6. PubMed ID: 21186534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The predictive value of ALT, HBeAg and HBV DNA levels at baseline and the degree of HBV suppression at week 12 adefovir dipivoxil treatment to the efficacy of it at week 52 in patients with HBeAg-positive chronic hepatitis B].
    Xie DY; Lin BL; Xu QH; Chen YM; Lu WL; Li JG; Gao ZL
    Zhonghua Gan Zang Bing Za Zhi; 2008 May; 16(5):341-4. PubMed ID: 18510844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.